Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy.
Chris Lange Friday's top analyst upgrades, downgrades and initiations include BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom and Disney.
Tuesday's top analyst upgrades, downgrades and initiations include Apollo Education, Petrobras, Shopify, Fitbit, Sarepta Therapeutics and Lowe's.
Sarepta Therapeutics announces the completion of the rolling submission of a New Drug Application to the FDA for eteplirsen.
Chris Lange Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to mention the enormous boost that shares are getting from short covering.
Chris Lange Wednesday's top analyst upgrades, downgrades and initiations include Achillion Pharmaceuticals, Computer Sciences, Keurig Green Mountain, Sarepta Therapeutics and Splunk.
Wednesday's top analyst upgrades, downgrades and initiations include Borderfree, Genworth Financial, Groupon, Nationstar Mortgage, SolarCity and Zulily.
Sarepta Therapeutics received a favorable rating from Merrill Lynch, and as a result the stock soared in Tuesday's trading session.
Thursday's top analyst upgrades, downgrades and initiations include Ally FInancial, Apple, Automatic Data Processing, Brocade Communications, Level 3 Communications and Tyco International.
Wednesday's leading analyst upgrades, downgrades and initiations from top research calls from around Wall Street include Exxon, Lowe's, Paycom Software, Under Armour, Wal-Mart and Verizon Communications.
Monday may have started out as a fairly quiet news day for most stock sectors on a shortened week, but don't tell that to the Ebola drug stocks.
Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble from a major news event.
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, October 28, 2014.
Sarepta Therapeutics shares took a big hit on Monday morning as disappointing news started its week out on the wrong foot.
Chris Lange ThinkstockJust when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again.…
